Anixa Biosciences, Inc. (NASDAQ: ANIX) is a Healthcare company (Biotechnology) with a market capitalization of $93M. The Maz Rating grades it against the other companies in its sector.
Anixa Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.67, Anixa Biosciences, Inc. trades at 6.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -70.4%, return on invested capital of -82.1% and a free cash flow yield of -7.9%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 8.54. Over the past 52 weeks the share price ranged from $2.32 to $5.46, with a beta of 0.60.
Anixa Biosciences, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of July 2026, Anixa Biosciences, Inc. (ANIX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 13.6% / 30% · Interest income / Revenue 11200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 13.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 11200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 13.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 11200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.14% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 92.9% / 33.33% · Receivables / Avg Assets (4Q) 0.09% / 33.33% · Interest income / Revenue 11200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 92.0% / 33.33% · (Cash+Recv) / Total Assets 92.0% / 33.33% · Interest income / Revenue 11200000.0% / 5% | Fail |
No. As of July 2026, Anixa Biosciences, Inc. (ANIX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Anixa Biosciences, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 11200000.0% of each dividend: Anixa Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated July 31, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.